Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...

Truist Financial analyst Nicole Germino maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of ...

Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor ...

On Thursday, H.C. Wainwright reaffirmed a positive stance on Sangamo BioSciences (NASDAQ:SGMO), maintaining a Buy rating and a $10.00 price target. Currently trading at $1.02 with a market ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co-develop a gene therapy for haemophilia A. Sangamo announced it will ...

Senti Biosciences has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is ...

Investing.com -- Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their partnership to co-develop a gene therapy for hemophilia A (HemoA), sending ...

Tuesday, Wells Fargo (NYSE:WFC) analyst revised the price target for Sangamo BioSciences (NASDAQ:SGMO) to $2.00 from the previous $3.00 while maintaining an Equal Weight rating on the stock. The ...

On Thursday, H.C. Wainwright reaffirmed a positive stance on Sangamo BioSciences (NASDAQ:SGMO), maintaining a Buy rating and a $10.00 price target. Currently trading at $1.02 with a market ...